HHS has said the US has purchased 500,000 treatment courses of Gilead Sciences' antiviral drug remdesivir, which includes all doses produced in July and 90% of production in August and September. HHS Secretary Alex Azar touted the agreement, but experts raised concerns about the US outbidding other countries instead of working collaboratively to manage access to remdesivir and other drugs or vaccines that may show promise.
US secures nearly all remdesivir for next 3 months
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.